Research on the Impact of the Centralized Drug Procurement Policy on China’s Pharmaceutical Enterprises  

作　　者：Miao Li Tian Lijuan 

机构地区：[1]School of Business Administration,Shenyang Pharmaceutical University,Shenyang 110016,China

出　　处：《Asian Journal of Social Pharmacy》2024年第4期351-360,共10页亚洲社会药学（英文）

基　　金：Research on the Technical System for Monitoring Adverse Drug Reactions/Events(Regulatory Technology System Research)(2019-0-4-040).

摘　　要：Objective To analyze the impact of the centralized drug procurement policy on pharmaceutical enterprises,and put forward some suggestions for improving China’s centralized drug procurement policy.Methods Through literature analysis and comparative research,the relevant policies and implementation effects from the“4+7”drug procurement pilot to the seventh batch of volume procurement were sorted out,and the impact of the procurement policy on pharmaceutical enterprises was analyzed.Results and Conclusion The centralized drug procurement policy has continuously improved the enthusiasm of enterprises to participate in bidding,and the consistency evaluation work has been carried out well.However,there are also some problems,such as the reduction of enterprise profits,the difficulty of enterprise operation,the decline in the quality of winning drugs,and the insufficient innovation ability and the supply capacity of enterprises.In this regard,enterprises should reasonably control the cost of drugs to ensure the stable supply of winning drugs.Besides,enterprises should create brand effect for their timely transformation and development.While strengthening pharmaceutical innovation,they can change from low-level generic drug production to R&D innovation.The government should pay close attention to the impact of centralized procurement on the quality and efficiency of enterprise drugs.For instance,the government should improve the pricing rules for drug procurement and increase supervision of drug quality and supply.At the same time,it should give certain policy and financial support to enterprises’technological innovation and talent introduction.

关 键 词：pharmaceutical collection purchase of pharmaceutical products in quantity procurement policy 

分 类 号：R95[医药卫生—药学]